Gen: Top 10 penalties for pharmaceutical companies in 2014, the champion was fined $650 million

Source: Xinkangjie / Dai Mingming 2015-02-06: for Biopharmaceutical Enterprises, the cost of law is expensive, especially when government agencies and courts see something wrong, whether it is to impose fines or to force companies to pay millions of costs to settle lawsuits In 2014, the total number of tickets on the list reached an astonishing 9 billion US dollars Although 99% of the ticket enterprises admitted to the punishment, some enterprises still refused to admit to the crime and the cases are still under trial The following are ten penalties issued by Gen for pharmaceutical enterprises in 2014, including various types of fines and indemnities Eight of them have paid more than $100 million In top 10, three cases were decided by institutions or courts outside the United States, including the European Union, China and Italy In a sense, the profits of Biopharmaceutical Enterprises sometimes cross the law, because most enterprises still support themselves in solving disputes without breaking the law They're just worried about bigger fines or sentences, and in extreme cases, a confrontation with the government may mean they won't be able to enter the market, and the loss will be even greater China's ticket reflects the efforts of President Xi Jinping's anti-corruption campaign Several drug companies in the anti corruption case are eager to expand the market of the world's most populous country But they pay a fine equivalent to 500 million dollars in the fight against corruption, and 5 of them are sentenced to fixed-term imprisonment Some companies accounted for two of the top 10 penalties, and another company appeared on the list three times #10 Pfizer fine: $35 million date: August 6, 2014, Pfizer settled lawsuits in 42 states in the United States due to improper marketing of the company's immunosuppressant rapamycin Pfizer denied any improper behavior, but agreed to settle the previous allegations of illegal marketing of rapamycin and the promotion of HYPERADAPTATION by the acquired Wyeth In addition, the prosecutor also proposed that Wyeth distort the use and benefits of rapamycin through interested doctors, including misleading information, funding hospitals and transplant centers, and encouraging doctors to use it for over indications Pfizer said that it would not promote the super adaptation, and would not boast about the safety and efficacy of other similar products without advantages It would not provide financial incentives for the super adaptation promotion of Pfizer products, put an end to the misleading or deceptive behavior of Pfizer products, and would not seek for non FDA products Approved protocols or orders for the admission of rapamycin also do not disseminate unapproved promotional information about rapamycin, unless such information and materials comply with FDA regulations Pfizer also pledged not to affect hospital prescribing behavior and clinical trials in transplant centers #9 Takeda / Lilly fine: $36.8 million time: October 27, 2014; April 7, 2014 Takeda and Lilly continued to appeal to the U.S District Court last year The two companies were previously accused of concealing the cancer risk of the anti diabetes drug Actos of the two companies, although the U.S District Judge Rebecca Doherty reduced the fine by 99% , the lawsuit is still between the patient and Takeda (case No.: 6:12-cv-00064) A jury in the Louisiana State Court has previously sentenced Takeda and Lilly to US $6 billion and US $3 billion respectively, and awarded us $1.475 billion to Terence Allen, who suffered from bladder cancer after taking Actos in 2006-2011 That year, FDA Ask Actos to increase the risk warning: taking more than one year can increase the risk of bladder cancer by 40% #8 GSK fine: $105 million time: on June 4, 2014, GSK agreed to pay $105 million to 44 states of the United States to achieve the illegal marketing of its asthma drugs, advair and antidepressants, Paxil and Wellbutrin GSK initially denied the violation In the case, GSK offered bonuses to marketers to encourage the promotion of drug super indications, while also increasing sales by bribing doctors The U.S said that GSK promoted Paxil to children and adolescents in 1999-2003, but did not explain its safety and effectiveness The drug may increase the suicide risk of patients In this regard, GSK did not provide sufficient data to FDA The United States also claims that GSK's promotion of Wellbutrin has gone beyond the scope of indications, including depression, weight loss, obesity, sexual dysfunction, attention deficit hyperactivity disorder, addiction, anxiety and two-way emotional disorder GSK has also been accused of mispromoting the asthma drug advair in 2000, and until 2010 the label of the drug was changed to be the first choice for asthmatics, including those who did not receive inhaled corticosteroids and those who only used short acting beta agonists The pharmaceutical giant has also been accused of failing to tell health care workers when clinical data on advair as the first choice for mild asthma are insufficient #7 Pfizer fine: $190 million time: on April 21, 2014, Pfizer agreed to settle a lawsuit against the company for delaying the entry of gabapentin generic drugs into the market, but Pfizer did not become the company's misconduct Pfizer said it was willing to pay $190 million to plaintiffs who bought gabapentin between November 11, 2002 and August 31, 2008 in order to end the 12-year lawsuit Prosecutors said Pfizer, in order to maintain its monopoly position, has been cracking down on generic drugs and promoting its super indications Buyers believe that Pfizer's actions forced them to pay a high price #6 Yuanteng international fine: US $192.7 million time: on February 21, 2014, yuanteng international and its subsidiary yuanteng pharmaceutical agreed to pay US $192.7 million to solve the public prosecution of the promotion of prescription medicine lidoderm Wisteria paid $137.7 million to the federal government and $34.2 million to the States The solution includes a stay of prosecution and a total fine of $20.8 million and $1719 in civil litigation In 2002-2006, the federal government filed a lawsuit against wisteria, accusing lidoderm, the company's product, of not complying with the Federal Food and drug and cosmetic act because it lacks sufficient evidence to treat pain, including unrelated postherpetic neuralgia, lumbago, diabetic neuropathy, and carpal tunnel syndrome Lidoderm was approved by the FDA only to relieve symptoms related to postherpetic neuralgia Washington also complained that some sales managers of Wisteria guided sales representatives to use lidoderm by misleading doctors, and encouraged clinic staff to promote lidoderm Wisteria agreed to settle civil litigation related to lidoderm in China, and the government said that from March 1999 to December 2007, the reimbursement submitted by Wisteria for Medicaid and non indications in the federal medical plan will not be accepted #5 Novartis / Roche fine: US $2.154 billion (US $106.8 million for Novartis and US $108.6 million for Roche) time: on February 21, 2014, Novartis and Roche were fined US $215.4 million by the Italian government for violating the anti-monopoly law According to the Italian competition bureau, the two companies colluded with the Italian state-owned medical institutions to mislead doctors to use the expensive ophthalmic drug Lucentis of the two companies And Avastin The agency said that since 2011, the two companies deliberately distinguish the two products for economic reasons Roche collects technology royalties from Lucentis, while Novartis directly benefits from Lucentis's improved sales The authorities believe that in 2012, the two companies caused a total of US $53 million in additional expenditures for the national health service, and the annual cost increase in the future may exceed US $708 million Novartis and Roche appealed immediately, but the Lazio regional administrative court upheld the verdict in December #4 Pfizer fine: $325 million time: November 10, 2014, May 30, 2014 Pfizer agreed to pay $325 million to settle third-party payers, including private insurance and government agency joint litigation, in one lawsuit sentenced by the U.S District Court The third party thinks that Pfizer has brought billions of dollars of losses to them due to the promotion of gabapentin The company declined to admit the violation, but said it would settle the dispute with all third-party payers and the state antitrust agency Pfizer subsidiary Warner Lambert agreed to pay $430 million in criminal and civil penalties after the plaintiff filed the lawsuit Pfizer's violations include the promotion of epilepsy and postherpetic neuralgia in adults beyond Neurontin These indications include attention deficit hyperactivity disorder, bipolar disorder, migraine and other pain Since Warner Lambert was acquired by Pfizer in 2000, Pfizer has stopped the promotion of super indications #3 GSK fine: 484.5 million US dollars time: on September 19, 2014, GSK was fined 3 billion yuan by Changsha intermediate people's Court of China, because the company's medical institutions in Hunan Province provided commercial bribery to medical personnel According to China's Xinhua news agency, in a private trial, the court held that the company had bribed to increase sales of its medical products The fine is the largest ever issued by a Chinese court to a pharmaceutical company Chinese officials then launched a year long investigation into GlaxoSmithKline's cash and sexual bribery In addition, the court sentenced five former GlaxoSmithKline executives #2 Krka, Lupin, mylan, Servier, Teva, neche / Unichem fine: $427.7 million time: on July 9, 2014, the European Commission punished a series of generic pharmaceutical companies, accusing them of reaching an agreement with Servier to delay Servier's best-selling antihypertensive drug perindopril With the introduction of generic drugs, the EU believes that the act has raised the public budget and violated the EU's anti-monopoly law When Servier lost the patent of perindopril structure in EU in 2003, its generic competitors still face many obstacles to enter the EU market From other forms of patent technology knife patents, Servier also obtained a higher level of patent protection in 2004 The European Union believes that Servier's patent protection blocked the efforts of the imitators Between 2005 and 2007, Servier and the imitators reached an agreement to delay the payment, which increased the EU's medical expenditure by tens of millions of euros All companies are against it, and they don't think it's against the law Servier said that patent extension is the key to the continuous development of any innovative drug #1 Boehringer Ingelheim fine: $650 million time: on May 28, 2014, Boehringer Ingelheim agreed to pay a fine of $650 million to settle up to 4000 lawsuits against pradaxa, a drug used to reduce blood lipid of the company by the United States federal and state governments The plaintiff believed that the bleeding caused by pradaxa was sometimes fatal The company insists that it has informed medical staff and patients about the effectiveness and safety of the drug, while the company does not admit improper behavior As many as 2500 pradaxa use cases were filed in the East St Louis court and another 1500 in the California state court At the trial, judge judge judge also fined the company $931000 because